Position in XENE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$10,052,958
-$3,257,518 QoQ
Shares Held
166,550
-27.2% QoQ
Ownership
0.172%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
#90
of 314 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XENE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ADAR1 Capital Management, LLC holds $1,760,528,411 across 192 Biotechnology names. XENE ranks #44 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,804,703 | $240,494,721 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
960,863 | $117,782,586 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,157,008 | $111,726,513 | |
| 4 | IMVT |
Immunovant, Inc.
|
2,330,716 | $89,802,487 | |
| 5 | ZLAB |
Zai Lab Ltd
|
3,369,034 | $64,011,646 | |
| 6 | AGIO |
Agios Pharmaceuticals, Inc.
|
1,288,053 | $47,799,646 | |
| 7 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
1,222,080 | $45,730,233 | |
| 8 | CYTK |
Cytokinetics Inc
|
457,907 | $39,009,097 |
All Filings in XENE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,052,958 | 166,550 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $13,310,476 | 228,899 | Shares | Sole | 2026-05-18 | |
| 2025-12-31 | $9,141,890 | 203,969 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $7,592,284 | 189,098 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $8,122,443 | 259,503 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $4,279,235 | 127,548 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,981,442 | 50,547 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $1,098,541 | 27,903 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $183,253 | 4,700 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||